November 30, 2016 - By Richard Conner · 0 Comments
The stock of Cel Sci Corporation (NYSEMKT:CVM) registered an increase of 3.34% in short interest. CVM’s total short interest was 2.46M shares in November as published by FINRA. Its up 3.34% from 2.38M shares, reported previously. With 630,700 shares average volume, it will take short sellers 4 days to cover their CVM’s short positions. The short interest to Cel Sci Corporation’s float is 2.08%. About 819,995 shares traded hands or 68.40% up from the average. CEL-SCI Corporation (NYSEMKT:CVM) has declined 61.40% since April 27, 2016 and is downtrending. It has underperformed by 66.63% the S&P500.
CEL-SCI Corporation is engaged in the research and development at developing the treatment of cancer and other diseases by using the immune system. The company has a market cap of $27.14 million. The Firm is focused on activating the immune system to fight cancer and infectious diseases. It currently has negative earnings. It operates through the segment of research and development of certain drugs and vaccines.
CEL-SCI Corporation, incorporated on March 22, 1983, is a biotechnology company. The Firm is engaged in the research and development of drugs and vaccines. The Firm researches and develops immunotherapy products for the treatment of cancer and infectious diseases. The Company’s product pipeline consists of Multikine (Leukocyte Interleukin, Injection) investigational immunotherapy against cancer and Human Papilloma Virus (HPV), and Ligand Epitope Antigen Presentation System (LEAPS) technology, with two investigational therapies, LEAPS-H1N1-DC pandemic flu treatment for hospitalized patients, and CEL-2000, a rheumatoid arthritis treatment vaccine.
More notable recent CEL-SCI Corporation (NYSEMKT:CVM) news were published by: Seekingalpha.com which released: “Cel-Sci Corporation: The Arbitration Is On, But Is The Phase III Trial Off?” on November 28, 2016, also Seekingalpha.com with their article: “A Closer Look At Cel-Sci Corporation Going Into Spring Of 2016” published on February 22, 2016, Businesswire.com published: “CEO Geert Kersten Summarizes CEL-SCI’s Phase 3 Cancer Immunotherapy Progress …” on February 23, 2016. More interesting news about CEL-SCI Corporation (NYSEMKT:CVM) were released by: Businesswire.com and their article: “CEL-SCI Corporation Reports Second Quarter Fiscal Year 2016 Financial Results” published on May 10, 2016 as well as Streetinsider.com‘s news article titled: “CEL-SCI Corp (CVM) Founder de Clara Resigns” with publication date: September 06, 2016.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.
By Richard Conner